Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №2 (2024) > Cardiovascular pathology in HIV-infection during antiretroviral therapy

Cardiovascular pathology in HIV-infection during antiretroviral therapy

Renata G. Tuaeva , Bella M. Tuglanova , Olga K. Loseva , Olga V. Zhukova , Margarita V. Nagibina , Timur P. Bessarab

For citation:


  • Abstract
  • About the Author
  • References

Abstract

A cardiac examination (ECG, Echo-CG and BCA ultrasound) was carried out on 150 patients – 60 HIV-infected with various stages of the disease and 90 patients with syphilis/HIV co-infection. Cardiovascular pathology caused by HIV infection was detected in 46.6% of patients in the first group, and in 7.7% in the second group. In a comparative analysis of the effect of antiretroviral therapy (ART) among those examined, it was proven that in the absence of ART or delayed or irregular use of drugs, the proportion of patients with cardiovascular pathology is several times higher than that of people who took ART on a timely and regular basis.
Key words: HIV infection, antiretroviral therapy, cardiovascular pathology in HIV infection, the effect of antiretroviral therapy on the development of cardiovascular pathology.

About the Author

Renata G. Tuaeva 1 , Bella M. Tuglanova 2 , Olga K. Loseva 3 , Olga V. Zhukova 4 , Margarita V. Nagibina 5 , Timur P. Bessarab 2

1 Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Moscow, Russia;

2 Moscow Medical Center for the Prevention and Control of AIDS, Moscow, Russia;

3 Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Moscow, Russia; Russian Biotechnological University, Moscow, Russia;

4 Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Moscow, Russia; Patrice Lumumba Peoples' Friendship University of Russia, Moscow, Russia;

5 Moscow Medical Center for the Prevention and Control of AIDS, Moscow, Russia; Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

References

1. Горячева О.Г., Козиолова Н.А., Терехина Н.А. ВИЧ-ассоциирован-ная патология сердечно-сосудистой системы. Российский кардио-логический журнал. 2019;24(11):148-54. DOI: 10.15829/1560-4071-2019-11-148-154 Goryacheva O.G., Koziolova N.A., Terekhina N.A. HIV-associated pathology of the cardiovascular system. Russian Journal of Cardiology. 2019;24(11):148-54. DOI: 10.15829/1560-4071-2019-11-148-154 (in Russian).
2. Чукаева И.И., Комарова И.В., Кравченко А.В. Гендерный фактор и риск развития факторов сердечно-сосудистых заболеваний у ВИЧ-инфицированных пациентов с сохраненной функцией им-мунной системы. Кардиологический вестник. 2013;VIII(2): 23-6. Chukaeva I.I., Komarova I.V., Kravchenko A.V. Gender factor and risk of development of cardiovascular disease factors in HIV-infected patients with preserved immune system function. Cardiological Bulletin. 2013;VIII(2):23-6 (in Russian).
3. Alvarez A, Orden S, Andújar I et al. Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. AIDS 2017;31(13):1781-95. DOI: 10.1097/QAD.0000000000001547
4. Belkin MN, Uriel N. Heart health in the age of highly active antiretroviral therapy: a review of HIV cardiomyopathy. Curr Opin Cardiol 2018;33(3):317-24. DOI: 10.1097/HCO.0000000000000513.
5. Dorjee K, Baxi SM, Reingold AL et al. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis 2017;17(1):708. DOI: 10.1186/s12879-017-2808-8
6. Friis-Moeller N, Reiss P, Sabin KA et al, DAD Research Group. The class of antiretroviral drugs and the risk of myocardial infarction. New England Journal of Medicine. 2007;356(17):1723-35. DOI: 10.1056/NEJMoa062744
7. Kelesidis T, Tran T, Brown T et al. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness. Antivir Ther 2017;22(2):113-26. DOI: 10.3851/IMP3093
8. Mahlab-Guri K, Asher I, Rosenberg-Bezalel S. Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients. Medicine (Baltimore) 2016;95(47). DOI: 10.1097/MD.0000000000005465
9. Nelson MD, Szczepaniak LS, LaBounty TM et al. Cardiac Steatosis and Left Ventricular Dysfunction in HIV-Infected Patients Treated With Highly Active Antiretroviral Therapy. JACC Cardiovasc Imaging 2014;7(11):1175-7. DOI: 10.1016/j.jcmg.2014.04.024
10. Rodríguez-Gallego E, Gómez J, Domingo P et al. Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. Atherosclerosis 2018;273:28-36. DOI: 10.1016/j.atherosclerosis.2018.04.008
11. Tsiodras S, Mantzoros C, Hammer S et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6.

For citation:Tuaeva R.G., Tuglanova B.M., Loseva O.K., Zhukova O.V., Nagibina M.V., Bessarab T.P. Cardiovascular pathology in HIV-infection during antiretroviral therapy. Clinical analysis in general medicine. 2024; 5 (2): 53–56 (In Russ.). DOI: 10.47407/kr2023.5.2.00388


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru